GSK's oncology unit TESARO achieved a partial legal win when a Delaware court dismissed AnaptysBio's counterclaim of anticipatory breach in their dispute over the dostarlimab cancer drug license. The court did not resolve the main contractual issues, and TESARO's claim for a declaratory judgment on their legal rights will continue to trial. The dispute arose from AnaptysBio's allegations that TESARO failed to meet certain license agreement terms from 2014, which GSK denies. Dostarlimab, marketed as Jemperli, is approved in over 35 countries for endometrial cancer and is seeing strong sales growth with ongoing trials for other cancer types.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
